Corix Bioscience, Inc.

Corix Bioscience, Inc.

CXBS
Corix Bioscience, Inc.US flagOther OTC
0.00
USD
- -
- -
2,734.00Market Cap

Total Valuation

Corix Bioscience, Inc. carries a market capitalization of 2,734.00, placing it among publicly traded companies globally. Its enterprise value stands at 16.28M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2,734.00
Enterprise Value16.28M

Share Statistics

Corix Bioscience, Inc. currently has 20.65M shares outstanding.

Shares Outstanding20.65M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 87.11, and the price-to-book ratio stands at -3.26.

PE RatioN/A
PS Ratio87.11
PB Ratio-3.26
P/TBV Ratio5.01
P/FCF Ratio-5.30
P/OCF Ratio-5.30

Enterprise Valuation

EV / Sales85.48
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

Corix Bioscience, Inc. maintains a current ratio of 5.11, meaning it holds 5.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.41, indicating moderate leverage, while an interest coverage ratio of -2.41 demonstrates limited ability to service its debt obligations.

Current Ratio5.11
Quick Ratio0.46
Debt / Equity1.41
Debt / EBITDA-0.06
Interest Coverage-2.41

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-68.82
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory TurnoverN/A

Stock Price Statistics

Corix Bioscience, Inc.'s stock has gained approximately 0.000003% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.

Beta (5Y)N/A
52-Week Price Change0.000003%
50-Day Moving Average0.00
200-Day Moving Average0.00
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Corix Bioscience, Inc. generated 190,411.00 in revenue and converted that into -5.64M in net income, yielding earnings per share of -0.13. EBITDA reached -857,119.00, while operating income came in at -905,733.00.

Revenue190,411.00
Gross ProfitN/A
Operating Income-905,733.00
Pretax Income-2.20M
Net Income-5.64M
EBITDA-857,119.00
EBIT-905,733.00
Earnings Per Share (EPS)-0.13

Balance Sheet

Corix Bioscience, Inc. holds 360,871.00 in cash and equivalents against 50,026.00 in total debt, resulting in a net debt position of -310,845.00. Total book value stands at -5.09M, with working capital of 3.23M providing operational flexibility.

Cash & Cash Equivalents360,871.00
Total Debt50,026.00
Net Debt-310,845.00
Equity (Book Value)-5.09M
Book Value Per Share-0.31
Working Capital3.23M

Cash Flow

Corix Bioscience, Inc. produced -3.13M in operating cash flow over the past twelve months. After subtracting 520.00 in capital expenditures, free cash flow totaled -3.13M - equivalent to -0.19 per share.

Operating Cash Flow-3.13M
Capital Expenditures520.00
Free Cash Flow-3.13M
FCF Per Share-0.19

Margins

Corix Bioscience, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -475.67 and net profit margin of -2,963.08 provide insight into operational efficiency.

Gross Margin100.00
Operating Margin-475.67
Pretax Margin-1,153.98
Profit Margin-2,963.08
EBITDA Margin-450.14

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield5.00
FCF Yield-18.88

Stock Splits

Corix Bioscience, Inc.'s most recent stock split took place on June 10, 2015 with a 1000:1 split ratio.

Last Split Date6/10/2015
Split Ratio1000:1

Scores

Corix Bioscience, Inc. posts an Altman Z-Score of 11.12, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score11.12